Yes, you are probably correct and not a 'meeting', but the intent and the outcome and importance to CytoDyn and any potential BP stands. This decision is key to our BLA decision and likely also to license discussions with BPs. I just re-listened to the recent PI interview and sounds like the decision has been made, but maybe CytoDyn hasn't received the official written approval to go with 525 mg? From 2:50 - 3:30 NP talks about 525 being the dose for combo and this being key to potential license agreements.

https://www.proactiveinvestors.com/companies/...00784.html